Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis-Reference-Cited by-同舟云学术

Achieving the composite end‐point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once‐weekly dulaglutide in Chinese patients with type 2 diabetes: A post‐hoc analysis

Published:2020-01-03 Issue:3 Volume:11 Page:647-652
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Xiao Xinhua¹,Wang Changjiang²,Lai Xiaoyang³,Zhang Bin⁴,Gu Liqun⁴,Hou Jianing⁵^ORCID,Zhou Zhiguang⁶

Affiliation:

1. Department of Endocrinology Key Laboratory of Endocrinology National Health Commission Chinese Academy of Medical Science Peking Union Medical College Hospital Beijing China

2. The First Hospital of Anhui Medical University Hefei China

3. The Second Affiliated Hospital of Nanchang University Nanchang China

4. Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai China

5. Clinical Research Physician Diabetes Therapeutic Area Eli Lilly and Company Lilly Suzhou Pharmaceutical Co. Ltd Shanghai China

6. Institute of Metabolism and Endocrinology Key Laboratory of Diabetes Immunology Ministry of Education National Clinical Research Center for Metabolic Diseases The Second Xiangya Hospital Central South University Changsha China

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13187

Reference21 articles.

1. Type 2 Diabetes Mellitus: A Review of Current Trends

2. Diagnosis and Classification of Diabetes Mellitus

3. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013

4. Knowledge of A1c Predicts Diabetes Self-Management and A1c Level among Chinese Patients with Type 2 Diabetes

5. A nationwide survey of diabetes education, self‐management and glycemic control in patients with type 2 diabetes in China;Guo XH;Chin Med J (Engl),2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes;BIO Web of Conferences;2023

2. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1;Diabetes Therapy;2020-03-26